Physiogenex will be presenting a new NASH hamster study at the 10th Aging Research and Drug Discovery (ARDD) Meeting in Copenhagen, Denmark, August 28th-September 1st, 2023.
The poster presentation, entitled “Semaglutide induces weight loss, reduces insulin resistance but does not improve non-alcoholic steatohepatitis and liver fibrosis in aged golden Syrian hamsters” will be delivered by Dr. François Briand, our Director of Research and Development, during the several poster sessions occuring during the meeting.
Feel free to contact us if you wish to set-up an appointment with Dr. Briand during the 10th ARDD and/or discuss your drug development projects with us.
Physiogenex is a leading preclinical research organization providing non clinical services in metabolic disorders and complications.
We offer in vivo translational diseases models as well as ex vivo assays to support efficacy and pharmacological assays. We have a strong expertise on metabolic diseases, diabetes, insulin resistance, obesity, dyslipidemia, liver diseases (NASH to fibrosis), cardiovascular and renal complications.